Friday, July 27, 2018 7:06:56 AM
3:57 am ET July 27, 2018 (Benzinga) Print
Nabriva Therapeutics plc (NASDAQ:NBRV) announced the pricing of its underwritten public offering of 18,181,818 ordinary shares at a public offering price of $2.75 per share. In addition, Nabriva Therapeutics has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,727,272 ordinary shares at the public offering price, less the underwriting discounts and commissions. All of the ordinary shares in the offering are to be sold by Nabriva Therapeutics.
The offering is expected to close on or about July 31, 2018, subject to customary closing conditions. Morgan Stanley is acting as sole book-running manager for the offering, Needham & Company, SunTrust Robinson Humphrey, and Wedbush PacGrow are acting as lead managers for the offering and Northland Capital Markets is acting as a manager for the offering.
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM